Format

Send to

Choose Destination
Eur Urol. 2018 Apr;73(4):521-523. doi: 10.1016/j.eururo.2017.12.021. Epub 2018 Jan 3.

Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.

Author information

1
The Royal Marsden NHS Foundation Trust, Sutton, London, England, UK; The Institute of Cancer Research, Sutton, London, England, UK.
2
The Royal Marsden NHS Foundation Trust, Sutton, London, England, UK; The Institute of Cancer Research, Sutton, London, England, UK. Electronic address: chris.parker@rmh.nhs.uk.

Abstract

In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel.

PMID:
29306513
DOI:
10.1016/j.eururo.2017.12.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center